spacer
home > ebr > spring 2019 > anticipating advancements
PUBLICATIONS
European Biopharmaceutical Review

Anticipating Advancements

Currently, around 1,000 clinical trials are taking place, with over 350 in the gene therapy area and over 30 of the gene therapy products in late-phase studies. While only one licenced product (Spark Therapeutics, Luxturna) is available, the FDA are predicting that 40 products will be licenced by 2020, with an anticipated 10 products being licenced per year.

Many of these products have been given ‘fast-track’ designation by the FDA and PRIME status by the EMA, accelerating their development with the aim of giving patients early access to these therapies.

The ongoing clinical success has led to an increased focus on the manufacturing of these products to meet the continuing demands for clinical studies and how requirements for commercial in-market supplies will be met. This not only relates to the manufacturing of specific vectors, but, also, the supply chains involved in the production of these materials within the clinical and commercial space.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Antony Hitchcock BSc is Technical Director at Cobra Biologics. He has over 30 years of experience in the large-scale manufacture of biopharmaceuticals. As a founding staff member of Cobra, Tony has been responsible for the development of much of Cobra’s manufacturing technologies in the field of DNA and virus production. He has held a number of senior roles, managing both manufacturing and development functions within the company, working on over 40 programmes for the development of novel therapeutic products including protein, recombinant virus, bacteriophage, and plasmid DNA products. His current role is based in the commercial group supporting external collaborations and outreach activities.
spacer
Antony Hitchcock BSc
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Regulatory bottlenecks mean EU clinicians and patients could lose access to medical devices under new rules

European clinicians and their patients could lose access to vital medical devices, including in-vitro diagnostics, due to a lack of agencies able to certify products in time to comply with strict new regulations.
More info >>

White Papers

Considerations for Choosing the Right Wearable Drug Delivery System

West Pharmaceutical Services, Inc.

For patients with chronic conditions, the use of injectable biologic therapies is on the rise. Biologics, while providing considerable therapeutic benefit, can also present several challenges for both drug manufacturers and patients. In particular, many biologics are highly viscous and others require large doses to be injected slowly over time. This can make it difficult to deliver a consistent dose every time, potentially impacting medication adherence.
More info >>

 
Industry Events

CPhI Korea

21-23 August 2019, COEX, Seoul, South Korea

CPhI Korea provides a dynamic meeting place for a wide range of industry suppliers to engage with purchasers and decision makers from the pharmaceutical industry in Korea and the surrounding region. The exhibition showcases the whole pharma supply chain from ingredients, contracting services to machinery and biopharmaceuticals. It also hosts an extensive conference programme covering the latest trends and topics within the regional market.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement